| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -24.3 | -9.8 |
| Net income | -24.3 | -9.8 |
| EPS (diluted, $ a share) | $-0.73 | $-4.53 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: SGP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
SpyGlass Pharma, Inc.: key numbers
- Share price
- $31.43Close, Nov 17
- Market cap
- $1.05B
- Shares outstanding
- 33.46MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from SpyGlass Pharma, Inc.
All →SpyGlass Pharma Financial Results
SpyGlass Pharma reported Q3 2026 financial results, highlighting a cash position of $215.8 million which is expected to fund operations through 2028. The company also announced the $13 million acquisition of Advanced Vision Science to secure IOL manufacturing capacity and reported positive four-year follow-up data from its first-in-human study of the BIM-IOL System.
- Term
- Q3 2026
“SpyGlass Pharma continued to execute our objectives over the course of the quarter as we aim to alter the treatment paradigm for glaucoma patients. Our underlying sustained drug delivery platform delivered four years of safety and efficacy results in the FIH trial of the BIM-IOL System, demonstrating that it can control IOP with unprecedented durability.”
Patrick Mooney, chief executive officer of SpyGlass Pharma
SpyGlass Pharma Clinical Trial Data
SpyGlass Pharma announced positive 4-year interim results from its first-in-human trial of the BIM-IOL System for glaucoma patients undergoing cataract surgery. The data showed a 37% reduction in mean intraocular pressure and 86% of patients remained off topical drops with no product-related adverse events reported.
- Term
- 4 years
SpyGlass Pharma Signs $13M M&A Deal with Advanced Vision Science, Inc.
SpyGlass Pharma acquired 100% of the equity of Advanced Vision Science, Inc. (AVS) from Santen Holdings US for approximately $13 million in cash. The deal secures internal manufacturing capacity for the intraocular lenses (IOL) used in SpyGlass's Phase 3 drug delivery system and includes a supply agreement to continue providing products to Santen in Japan.
- Value
- $13M
- Counterparty
- Advanced Vision Science, Inc.